From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2003
Last Reported 2007
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.74
Pain Relevance 0.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (HSD17B1) small molecule metabolic process (HSD17B1) oxidoreductase activity (HSD17B1)
cytoplasm (HSD17B1)
Anatomy Link Frequency
sympathetic 1
HSD17B1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 3 94.48 High High
Clonidine 1 93.28 High High
agonist 3 88.92 High High
Bile 39 81.36 Quite High
nud 2 5.00 Very Low Very Low Very Low
Migraine 1 5.00 Very Low Very Low Very Low
adenocard 1 5.00 Very Low Very Low Very Low
Inflammatory marker 1 5.00 Very Low Very Low Very Low
Cholecystokinin 1 5.00 Very Low Very Low Very Low
Sumatriptan 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Obesity 7 99.42 Very High Very High Very High
Impaired Glucose Tolerance 1 92.84 High High
Insulin Resistance 1 91.88 High High
Repression 6 86.60 High High
Metabolic Disorder 1 57.40 Quite High
Hyperglycemia 3 55.04 Quite High
Coronary Artery Disease 25 50.00 Quite Low
Atherosclerosis 13 50.00 Quite Low
Diabetes Mellitus 29 41.64 Quite Low
Disorder Of Lipid Metabolism 23 31.76 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We conclude that possible distinct hypothalamic mediators regulating adipose tissue 11 beta-HSD-1 might include down-regulation of 11 beta-HSD-1 activity by CRH, ACTH, and alpha 2 sympathetic stimulation, and up-regulation of the enzyme by beta 2 sympathetic stimulation and by the cytokines TNFalpha and IL-1 beta.
Spec (might) Negative_regulation (down-regulation) of beta-HSD-1 in sympathetic associated with obesity and cytokine
1) Confidence 0.32 Published 2003 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12519881 Disease Relevance 0.17 Pain Relevance 0.22
Specifically, increased LXR activity downregulates 11 beta-hydroxysteroid dehydrogenase type 1 (Stulnig et al 2002), downregules PPAR gamma, coactivator-1 alpha, and gluconeogenic enzymes such as PEPCK and glucose-6-phosphatase (Cao et al 2003; Laffitte et al 2003) and increases expression of glucokinase and GLUT-4 (Laffitte et al 2003).
Negative_regulation (downregulates) of beta-hydroxysteroid dehydrogenase type 1
2) Confidence 0.06 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.57 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools